{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:04:34Z","timestamp":1784649874328,"version":"3.55.0"},"reference-count":109,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Palliative systemic therapy for advanced thymic epithelial tumors (TET) is challenging due to scarce evidence and biological heterogeneity. Scientific discussion, as in this review, is limited to cross-trial comparisons of small, non-randomized studies. Platinum-based combination chemotherapy is the standard first-line treatment. Here, we challenge the addition of anthracyclines to platinum in thymoma. We critically appraise new combinations with antiangiogenic drugs and immune checkpoint inhibitors (ICI) in thymic carcinoma and their implications for therapy sequences. We review the data on classic genomics-based targeted therapy that does not benefit most patients and explore established and upcoming biomarkers including KIT and HER2. Finally, we discuss investigational therapies like anti-TROP2 antibody\u2013drug conjugates and proteasome inhibitors, as well as topics and design of future research.<\/jats:p>","DOI":"10.3390\/cancers18142354","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:17:52Z","timestamp":1784647072000},"page":"2354","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Palliative Systemic Therapy in Advanced Thymic Epithelial Tumors in 2026\u2014A Narrative Review"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4095-8649","authenticated-orcid":false,"given":"Felix C.","family":"Saalfeld","sequence":"first","affiliation":[{"name":"Department for Internal Medicine I, Medical Faculty and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Fetscherstr. 74, 01307 Dresden, Saxony, Germany"},{"name":"Thoracic Oncology Group, National Center for Tumor Diseases (NCT) Dresden, Fetscherstr. 74, 01307 Dresden, Saxony, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2579-0171","authenticated-orcid":false,"given":"Tobias R.","family":"Overbeck","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, University Medical Center G\u00f6ttingen, G\u00f6ttingen University, Robert-Koch-Str. 40, 37075 G\u00f6ttingen, Lower Saxony, Germany"},{"name":"Lung Tumor Center, University Medical Center G\u00f6ttingen, G\u00f6ttingen University, Robert-Koch-Str. 40, 37075 G\u00f6ttingen, Lower Saxony, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jtho.2021.09.017","article-title":"Introduction to 2021 WHO Classification of Thoracic Tumors","volume":"17","author":"Tsao","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.annonc.2024.06.002","article-title":"Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)","volume":"35","author":"Proto","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2020.11.011","article-title":"Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: A RYTHMIC study","volume":"143","author":"Molina","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.athoracsur.2014.04.028","article-title":"A meta-analysis of surgical versus nonsurgical management of recurrent thymoma","volume":"98","author":"Hamaji","year":"2014","journal-title":"Ann. Thorac. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.athoracsur.2020.05.088","article-title":"Management and Long-Term Outcomes of Advanced Stage Thymoma in the United States","volume":"111","author":"Khorfan","year":"2021","journal-title":"Ann. Thorac. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Qi, W., and Tian, H. (2022). The role of surgery in advanced thymic tumors: A retrospective cohort study. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1073641"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: A clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann. Thorac. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2021.11.028","article-title":"Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network","volume":"162","author":"Petat","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S1749","DOI":"10.1097\/JTO.0b013e31821ea5f7","article-title":"Chemotherapy definitions and policies for thymic malignancies","volume":"6","author":"Girard","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e70174","DOI":"10.1111\/jne.70174","article-title":"European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids","volume":"38","author":"Baudin","year":"2026","journal-title":"J. Neuroendocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2025.0027","article-title":"Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology","volume":"23","author":"Riely","year":"2025","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2016.03.012","article-title":"Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria","volume":"96","author":"Kim","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00432-014-1800-6","article-title":"Key components of chemotherapy for thymic malignancies: A systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy","volume":"141","author":"Okuma","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8111","DOI":"10.1200\/JCO.2024.42.16_suppl.8111","article-title":"A retrospective study of 157 patients comparing platinum-anthracycline to other platinum combination for untreated unresectable thymoma: NEJ023B","volume":"42","author":"Saito","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.bjc.6604480","article-title":"Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer","volume":"99","author":"Baka","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jnci\/93.4.300","article-title":"Etoposide plus cisplatin with or without the combination of 4\u2032-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: A French Federation of Cancer Institutes multicenter phase III randomized study","volume":"93","author":"Pujol","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): A multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Mandjes","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jamaoncol.2019.0001","article-title":"Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial","volume":"5","author":"Nomura","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"Ntentas","year":"2017","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41416-018-0159-x","article-title":"Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer","volume":"119","author":"Boekel","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103532","DOI":"10.1016\/j.jtho.2025.12.002","article-title":"The Risk of Cardiovascular Adverse Outcomes in Patients With Thymoma or Thymic Carcinoma Receiving Cancer Therapy","volume":"21","author":"Zhan","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"111546","DOI":"10.1016\/j.radonc.2026.111546","article-title":"Cardiac adverse events following post-operative radiation therapy in patients with thymic malignancies","volume":"220","author":"Icht","year":"2026","journal-title":"Radiother. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.31144","article-title":"Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients","volume":"124","author":"Rosenstock","year":"2018","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"112952","DOI":"10.1016\/j.ejca.2023.112952","article-title":"Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy","volume":"191","author":"Lee","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.6004\/jnccn.2025.0006","article-title":"Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology","volume":"23","author":"Inaba","year":"2025","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"851","DOI":"10.6004\/jnccn.2023.0040","article-title":"Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Bhatia","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.18632\/aging.202332","article-title":"Dexrazoxane ameliorates radiation-induced heart disease in a rat model","volume":"13","author":"Li","year":"2021","journal-title":"Aging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1634\/theoncologist.2017-0586","article-title":"Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study","volume":"23","author":"Ko","year":"2018","journal-title":"Oncologist"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/jjco\/hyz167","article-title":"Thymic epithelial tumor treatment in Japan: Analysis of hospital cancer registry and insurance claims data, 2012-2014","volume":"50","author":"Kanemura","year":"2020","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/1759-7714.15198","article-title":"Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience","volume":"15","author":"Ho","year":"2024","journal-title":"Thorac. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1470-2045(25)00001-4","article-title":"Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): A multicentre, single-arm, phase 2 trial","volume":"26","author":"Shukuya","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1200\/JCO.2025.43.16_suppl.8109","article-title":"A prospective, single-arm, phase II trial of adebrelimab plus nab-paclitaxel and carboplatin in patients with unresectable advanced metastatic or recurrent thymic carcinomas","volume":"43","author":"Xu","year":"2025","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: A randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_40","first-page":"100738","article-title":"S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma","volume":"5","author":"Tsao","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_41","first-page":"S2066","article-title":"P1.17-014 Platinum Rechallenge in Advanced Thymic Epithelial Tumors: Still an Option in the Age of Target Therapy? A Monocentric Experience","volume":"12","author":"Ottaviano","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/cam4.5053","article-title":"Second-line treatment options in advanced thymic carcinoma after failure of platinum-based chemotherapy: A multicenter retrospective study","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1378\/chest.110.4.1115","article-title":"Retreatment of recurrent invasive thymoma with platinum, doxorubicin, and cyclophosphamide","volume":"110","author":"Lara","year":"1996","journal-title":"Chest"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An Eastern Cooperative Oncology Group Phase II Trial","volume":"22","author":"Loehrer","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Montella, L., Ottaviano, M., Morra, R., Pietroluongo, E., Placido, P.d., Tortora, M., Sorrentino, C., Facchini, G., Placido, S.d., and Giuliano, M. (2022). The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?. Cancers, 14.","DOI":"10.3390\/cancers14030774"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Yang, H., Wang, Y., Pan, Z., Liu, Z., Cheng, B., and Qi, G. (2025). Methylprednisolone pulse versus docetaxel in recurrent thymoma with myasthenia gravis. Front. Neurol., 16.","DOI":"10.3389\/fneur.2025.1615529"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/cncr.21875","article-title":"Preoperative steroid pulse therapy for invasive thymoma: Clinical experience and mechanism of action","volume":"106","author":"Kobayashi","year":"2006","journal-title":"Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.resinv.2024.06.008","article-title":"The remarkable antitumor efficacy of corticosteroid treatment in patients with refractory thymomas","volume":"62","author":"Tanaka","year":"2024","journal-title":"Respir. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e70214","DOI":"10.1111\/1759-7714.70214","article-title":"Neoadjuvant Glucocorticoids Facilitate Resection in Advanced B-Type Thymomas: A Propensity-Matched Analysis of Surgical and Survival Outcomes","volume":"17","author":"Yu","year":"2026","journal-title":"Thorac. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2022.12.005","article-title":"Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis","volume":"180","author":"Remon","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"100419","DOI":"10.1016\/j.esmoop.2022.100419","article-title":"Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers","volume":"7","author":"Tabernero","year":"2022","journal-title":"ESMO Open"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jtho.2020.11.003","article-title":"Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up","volume":"16","author":"Giaccone","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S1470-2045(25)00300-6","article-title":"Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): A single-arm, phase 2 trial","volume":"26","author":"Remon","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): A multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"105301","DOI":"10.1016\/j.esmoop.2025.105301","article-title":"Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings","volume":"10","author":"Takagi","year":"2025","journal-title":"ESMO Open"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2217\/fon.14.144","article-title":"Capecitabine plus gemcitabine in thymic epithelial tumors: Final analysis of a Phase II trial","volume":"10","author":"Palmieri","year":"2014","journal-title":"Future Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/annonc\/mdp483","article-title":"Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)","volume":"21","author":"Palmieri","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Kirzinger, L., Boy, S., Marienhagen, J., Schuierer, G., Neu, R., Ried, M., Hofmann, H.-S., Wiebe, K., Str\u00f6bel, P., and May, C. (2016). Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168215"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.jtho.2018.07.094","article-title":"A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma","volume":"13","author":"Gbolahan","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.21037\/jtd.2019.06.65","article-title":"S-1 salvage chemotherapy for stage IV thymic carcinoma: A study of 44 cases","volume":"11","author":"Wang","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial","volume":"37","author":"Cho","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: A single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"101576","DOI":"10.1016\/j.esmoop.2023.101576","article-title":"Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial","volume":"8","author":"Girard","year":"2023","journal-title":"ESMO Open"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"8016","DOI":"10.1200\/JCO.2025.43.16_suppl.8016","article-title":"Efficacy and safety of nivolumab plus ipilimumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial","volume":"43","author":"Girard","year":"2025","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: An open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jtho.2023.04.009","article-title":"STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines","volume":"18","author":"Proto","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(22)00542-3","article-title":"Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): A single-arm, multicentre, phase 2 trial","volume":"23","author":"Conforti","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jtho.2022.10.008","article-title":"A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21)","volume":"18","author":"Jung","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2019.09.015","article-title":"Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies","volume":"137","author":"Hellyer","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/CAD.0000000000001473","article-title":"Anlotinib in patients with relapsed or refractory thymic epithelial tumors: A study of 50 cases","volume":"34","author":"Wang","year":"2023","journal-title":"Anti-Cancer Drugs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1080\/14796694.2025.2592721","article-title":"Real-world treatment patterns and attrition for non-driver mutation metastatic non-small cell lung cancer in the US","volume":"21","author":"Schoenfeld","year":"2025","journal-title":"Future Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.3390\/curroncol29080460","article-title":"Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT)","volume":"29","author":"Dediu","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1056\/NEJMoa2510308","article-title":"Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC","volume":"394","author":"Planchard","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Shimamura, S.S., Shukuya, T., Asao, T., Hayakawa, D., Kurokawa, K., Xu, S., Miura, K., Mitsuishi, Y., Tajima, K., and Shibayama, R. (2022). Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a \u201ctail plateau\u201d in the survival curve of these patients?. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09421-7"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/annonc\/mdv012","article-title":"Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial","volume":"26","author":"Masi","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"103159","DOI":"10.1016\/j.ctrv.2026.103159","article-title":"PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes","volume":"147","author":"Marinelli","year":"2026","journal-title":"Cancer Treat. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"36","DOI":"10.21037\/med-23-48","article-title":"Insights into molecular aspects and targeted therapy of thymic carcinoma: A narrative review","volume":"8","author":"Sakane","year":"2024","journal-title":"Mediastinum"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"100612","DOI":"10.1016\/j.medj.2025.100612","article-title":"Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors","volume":"6","author":"Rostock","year":"2025","journal-title":"Med"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cllc.2020.11.010","article-title":"Mutation Profile of Thymic Carcinoma and Thymic Neuroendocrine Tumor by Targeted Next-generation Sequencing","volume":"22","author":"Sakane","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2016.12.005","article-title":"Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)","volume":"104","author":"Tiseo","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/oncolo\/oyac115","article-title":"Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers","volume":"27","author":"Girard","year":"2022","journal-title":"Oncologist"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/annonc\/mdr626","article-title":"Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors","volume":"23","author":"Schirosi","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The Integrated Genomic Landscape of Thymic Epithelial Tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3892\/mco.2016.752","article-title":"c-kit mutation-positive advanced thymic carcinoma successfully treated as a mediastinal gastrointestinal stromal tumor: A case report","volume":"4","author":"Hirai","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Hartmann","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21037\/med-2025-1-48","article-title":"HER2 expression and HER2 gene amplification in thymic epithelial tumors: A narrative review","volume":"10","author":"Agrafiotis","year":"2026","journal-title":"Mediastinum"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","article-title":"Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer","volume":"394","author":"Wolpin","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s13063-020-04248-8","article-title":"Sample size calculation in randomised phase II selection trials using a margin of practical equivalence","volume":"21","author":"Dehbi","year":"2020","journal-title":"Trials"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Berry, D.A. (2025). Adaptive Bayesian Clinical Trials: The Past, Present, and Future of Clinical Research. J. Clin. Med., 14.","DOI":"10.3390\/jcm14155267"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"100861","DOI":"10.1016\/j.lanepe.2024.100861","article-title":"Management of patients with rare adult solid cancers: Objectives and evaluation of European reference networks (ERN) EURACAN","volume":"39","author":"Blay","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cllc.2024.02.002","article-title":"Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin\/Paclitaxel\/Lenvatinib\/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas","volume":"25","author":"Okuma","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Zhong, T., Huang, Z., Pang, X., Jin, C., He, X., Montoya, J., Chang, B., Xia, M., Li, B., and Min, J. (2023). 1194 Mechanism of action of ivonescimab (AK112\/SMT112): A first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects. Regular and Young Investigator Award Abstracts; SITC 38th Annual Meeting (SITC 2023) Abstracts, BMJ Publishing Group Ltd.","DOI":"10.1136\/jitc-2023-SITC2023.1194"},{"key":"ref_97","first-page":"e77381","article-title":"Efficacy and Safety of Ivonescimab in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC): A Systematic Review","volume":"17","author":"Hammadeh","year":"2025","journal-title":"Cureus"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e15000","DOI":"10.1200\/JCO.2023.41.16_suppl.e15000","article-title":"First-in-human, phase I study of KC1036, a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors","volume":"41","author":"Li","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s10456-025-10008-6","article-title":"KC1036, a multi-kinase inhibitor with anti-angiogenic activity, can effectively suppress the tumor growth of Ewing sarcoma","volume":"28","author":"Ou","year":"2025","journal-title":"Angiogenesis"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"101430","DOI":"10.1016\/j.eclinm.2022.101430","article-title":"Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours","volume":"49","author":"Karp","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1158\/1538-7445.AM2025-5819","article-title":"Abstract 5819: Anti-cancer immune effects of PT-112 monotherapy across two disease indications","volume":"85","author":"Rajan","year":"2025","journal-title":"Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e20647","DOI":"10.1200\/JCO.2023.41.16_suppl.e20647","article-title":"Preliminary efficacy, safety, and immunomodulatory effects of PT-112 from a phase 2 proof of concept study in patients (pts) with thymic epithelial tumors (TETs)","volume":"41","author":"McAdams","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_103","first-page":"100693","article-title":"Trophoblast Cell Surface Antigen 2 Expression in Thymic Carcinoma: Brief Report","volume":"5","author":"Kurokawa","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.lungcan.2016.09.015","article-title":"Expression of mesothelin in thymic carcinoma and its potential therapeutic significance","volume":"101","author":"Thomas","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"26744","DOI":"10.18632\/oncotarget.15814","article-title":"Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma","volume":"8","author":"Inaguma","year":"2017","journal-title":"Oncotarget"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1158\/1535-7163.MCT-22-0073","article-title":"Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors","volume":"21","author":"Tomar","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO-25-00363","article-title":"Phase I Dose-Escalation Results for the Delta-Like Ligand 3\/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas","volume":"43","author":"Wermke","year":"2025","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"LB-A003","DOI":"10.1158\/2326-6074.IO2026-LB-A003","article-title":"Abstract LB-A003: Efficacy and safety of the DLL3\/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing Phase I trial","volume":"14","author":"Capdevila","year":"2026","journal-title":"Cancer Immunol. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41419-025-08240-5","article-title":"Proteasome inhibition as a potential therapeutic target in thymic cancer","volume":"16","author":"Okada","year":"2025","journal-title":"Cell Death Dis."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2354\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:25:41Z","timestamp":1784647541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":109,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142354"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142354","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}